Acrongenomics, Inc. Retains KGMC Group, LLC.

FRANKFORT, Ill. -- Acrongenomics, Inc. (OTCBB:AGNM) is pleased to announce that it has retained KGMC Group, LLC of Frankfort, Illinois to introduce its cutting-edge Nano-JETA(TM) technology platform to the world market.

Privately-held KGMC Group LLC (www.kgmcgroup.com) introduces and markets advanced medical technologies. With a diverse team of talented and respected professionals in medicine, science, business, finance, marketing and law from four continents, KGMC provides services and solutions essential to converting emerging technologies into viable business ventures. KGMC Group LLC will work with Acrongenomics to complete formal validations of the advanced Nano-JETA(TM) platform, secure publications of this breakthrough technology in respected medical and scientific journals and identify ideal partners to commercialize the technology.

"Following a year of thorough study, our scientists and Board of Directors have confirmed that Acrongenomics' know-how in nanotechnology has resulted in compelling breakthroughs, significantly impacting our battle with various diseases such as cancer. We are convinced that Nano-JETA(TM) technology platform can accelerate and enhance the commonly used Real Time PCR amplification process, so that it is rendered 100% accurate in detecting genetic diseases such as cancer. Neo-EpCAM(TM) cancer detection assay is the first application utilizing the Nano-JETA(TM) technology. More so exciting is that the process takes less than two minutes. Because it is fast, inexpensive, easy to administer, non-invasive, accurate, specific and uses existing equipment, we are convinced that the technology will assist physicians in detecting genetic diseases quickly, accurately and early enough to potentially save lives and avoid much cost and anguish. Now confident in the technology, we will assist Acrongenomics in securing a partner to further develop and market such technology," Says KGMC Group President Bill Kanatas.

Acrongenomics Inc. (www.acrongen.com) (OTCBB:AGNM) is a publicly traded research and development nanobiotechnology company pioneering the development of uniquely advanced nano-molecular diagnostics for the Life Sciences Industry. The Company is seeking to establish its proprietary nanotechnology platform as a global standard in Molecular In Vitro Diagnostics.

Acrongenomics has successfully conducted laboratory tests and clinical trials for the cancer detection and quantification process. The technology has been applied to major Molecular Diagnostics techniques such as Polymerase Chain Reaction (PCR) and Real-Time PCR producing outstanding results in terms of sensitivity, reproducibility, specificity and speed with the use of conventional equipment.

Since the completion of the Human Genome project in 2000, the growing number of sequencing and functional genomic initiatives has resulted in the rapid growth of the Molecular Diagnostics field. In 2005, the global market for molecular diagnostics is estimated to reach $6.5 billion. By 2010 the market is forecasted to expand to $12 billion and to $35 billion by 2015 (Research & Markets Report 2004). There is considerable demand for new molecular diagnostic technologies. So profitable is the molecular diagnostics market that pharmaceutical and biotechnology companies are highly focused in developing molecular diagnostics tests that can be used to individualize patient treatments.

With the validation and introduction of the Nano-JETA(TM) technology platform, along with the support of KGMC Group LLC, Acrongenomics is positioned to emerge as a leader in this rapidly expanding market segment.